1 Memorial Sloan-Kettering Cancer Center and Weill Cornell ...

35. M.L. Davila, C.Taylor, X.Wang, J. Stefanski, M. Olszewska, S. Bartido, M. Frattini, M. Sadelain, I. Rivière,R.J. Brentjens. B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia FollowingRe-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen (Abstract# 3268). 52 nd ASH Annual Meeting, December 2010 Orlando, FL.36. J. H. Park, R. Yeh, I. Rivière, M. Sadelain, and R. J. Brentjens. In Vitro analysis of Suicide Gene Expressionand Function of 3 Suicide Gene-Prodrug Combinations In Human T Lymphocytes Further Modified to Expressthe CD19 Targeted 19-28z Chimeric Antigen Receptor (Abstract # 3771). 52 nd ASH Annual Meeting,December 2010, Orlando, FL.37. K. Curran, C. Taylor, E. Doubrovina, X. Wang, R. O’Reilly, M. Sadelain, N. Kernan, R.J. Brentjens, I. Rivère.Validation of Donor Derived Virus Specific T-Lymphocytes Genetically Modified To Target the CD19 Antigenfor the Treatment of Relapsed Leukemia (Abstract # 230). American Society of Gene and Cell Therapy(ASGCT) 14 th Annual Meeting, May 18 – 22, 2011, Seattle, WA.38. H.J. Pegram, V. La Russa, R.J. Brentjens. Expansion and Anti-Tumor Efficacy of CD19 Targeted Cord BloodT Cells (Abstract # 239). American Society of Gene and Cell Therapy (ASGCT) 14 th Annual Meeting, May 18– 22, 2011, Seattle, WA.39. A.A. Chekmasova, S. Sandadi, Y. Nikhamin, D.R. Spriggs, R.J. Brentjens. Effective Eradication ofEstablished Ovarian Murine Tumors with MUC16 Targeted T Cells Expressing IL-12 Gene (Abstract # 495).American Society of Gene and Cell Therapy (ASGCT) 14 th Annual Meeting, May 18 – 22, 2011, Seattle, WA.40. T. Tsukahara, K. Ohmine, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, I. Rivère, M. Sadelain, R.J.Brentjens, K. Ozawa. Anti-Tumor Activity of Engineered T Lymphocytes Expressing an Anti-CD19 CAR forB Cell Lymphoma (Abstract # 791). American Society of Gene and Cell Therapy (ASGCT) 14 th AnnualMeeting, May 18 – 22, 2011, Seattle, WA.41. R. J. Brentjens, I. Riviere, J. Park, M. Davilla, X. Wang, R. Yeh, N. Lamanna, M. G. Frattini, M. Sadelain.Lymphodepletion and tumor burden govern clinical responses in patients with B-cell malignancies treated withautologous, CD19-targeted T cells (Abstract# 2534). American Society of Clinical Oncology (ASCO) 47 thAnnual Meeting, June 3 – 7, 2011, Chicago, IL.42. J R Gardner, K. Knapp, M.G. Frattini, N. Lamanna, R. Brentjens, J.G Jurcic, P G. Maslak, E. Berman,M..Weiss, D. A. Scheinberg, M. Heaney. Elevated Mitochondrial Membrane Potential in CLL Cells IsAssociated with a more aggressive Natural History (Abstract # 1765). American Society of Hematology (ASH)53 rd Annual Meeting, Dec. 10 – 13, 2011, San Diego, CA.43. H. J. Pegram, J. Lee, E. Hayman, G. H Imperato, T. J. Tedder, R. J Brentjens. Tumor Specific T CellsModified to Secrete IL-12 Eradicate Systemic Tumors in the Absence of Prior Toxic ChemotherapyConditioning Regimens. (Abstract # 3120). American Society of Hematology (ASH) 53 rd Annual Meeting, Dec.10 – 13, 2011, San Diego, CA.44. J. H. Park, R. Yeh, I. Riviere, M. Sadelain, R. Brentjens. In Vivo comparison of 3 Suicide Gene-ProdrugCombinations in a Mouse Graft-Versus-Host-Disease Model (Abstract # 3121). American Society ofHematology (ASH) 53 rd Annual Meeting, Dec. 10 – 13, 2011, San Diego, CA.45. A. A Chekmasova, S. Sandadi, D. R Spriggs, R. J Brentjens. Enhanced Antitumor Efficacy of MUC-16Targeted T Cells Further Modified to Constitutively Express the IL-12 Cytokine in a Syngeneic Model ofOvarian Cancer. (Abstract # 4176). American Society of Hematology (ASH) 53 rd Annual Meeting, Dec. 10 –13, 2011, San Diego, CA.21